Synchron’s flagship StentrodeTM endovascular implant does not require open brain surgery and has obtained FDA Breakthrough Device Designation for the treatment of paralysisThe New York based company is already conducting human trials in Australia and is expected to commence a U.S. clinical trial in 2021NEW YORK (BUSINESS WIRE) Synchron, a brain interface platform company,